Abstract
Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Current Pharmaceutical Design
Title: Helicobacter pylori Current Chemotherapy and New Targets for Drug Design
Volume: 7 Issue: 5
Author(s): John S. Williamson
Affiliation:
Keywords: Helicobacter pylori, Gastritis, Non-ulcer dyspepsia, Peptic ulcer disease, Gastric cancers, Compylobacter jejuni, Adhesion factor, Urease, Inflammation, VacA
Abstract: Helicobacter pylori infection is a major cause of many diseases of the gastrointestinal tract, including gastritis, non-ulcer dyspepsia, peptic ulcer disease, and gastric cancers. It is estimated that more than half of the human race is affected by this organism. Although effective treatments are available which will eliminate the organism in about 90percent of cases in developed countries, the pandemic occurrence of Helicobacter pylori infection coupled with its ability to develop resistance to our current arsenal of antimicrobial regimens and subsequently reinfect patients makes the pathogenic potential of this microorganism a major global health concern. Provided is a review of the current and evolving therapeutic regimens used in the eradication of Helicobacter pylori, the difficulties associated with in vitro drug screening, as well as potentially new therapeutic targets. In addition, the discovery, the unique physiology, biochemistry, and pathogenicity of this remarkable microorganism is examined.
Export Options
About this article
Cite this article as:
Williamson S. John, Helicobacter pylori Current Chemotherapy and New Targets for Drug Design, Current Pharmaceutical Design 2001; 7 (5) . https://dx.doi.org/10.2174/1381612013397979
DOI https://dx.doi.org/10.2174/1381612013397979 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Exploration of Structure-Based on Imidazole Core as Antibacterial Agents
Current Topics in Medicinal Chemistry Design, Synthesis and Biological Evaluation of a Novel Series of Indole-3- Carboxamide Derivatives for Cancer Treatment as EGFR Inhibitors
Letters in Drug Design & Discovery Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Molecular Docking Studies of Novel Thiosemicarbazone-based Indoles as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery Expression of Angiogenesis-related Genes in a Group of Iranian Cases of Breast Cancer
Current Pharmacogenomics and Personalized Medicine Glycans in Magnetic Resonance Imaging: Determinants of Relaxivity to Smart Agents, and Potential Applications in Biomedicine
Current Medicinal Chemistry The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Methylation of ZNF331 Promotes Cell Invasion and Migration in Human Esophageal Cancer
Current Protein & Peptide Science Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Triazole as Potent Anti-cancer Agent- A Pharmacophoric Scaffold
Current Cancer Therapy Reviews Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Genomic Organization and Control of the Grb7 Gene Family
Current Genomics